Answers are grounded in this paper and cite their sources.
. Our data suggested that anti-HSP90 and anti-HDAC6 are promising strategies to treat TNBC and ERα+ breast cancers respectively, and anti-HDAC6 can be considered during treatment of tamoxifen-resistance breast cancers.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: